PhaseBio: Ji Xing Buys Global Rights for Hypertension Candidate from PhaseBio

Shanghai Ji Xing Pharma bought global rights to a preclinical hypertension asset from PhaseBio Pharmaceuticals, a Philadelphia area company currently in bankruptcy. PB6440 is a next-gen selective aldosterone synthase inhibitor. In preclinical tests, the candidate inhibited aldosterone synthase but did not interfere with a homologous enzyme that is key to cortisol synthesis. Ji Xing brings novel drugs to China patients who have serious unmet medical needs. Terms of the agreement were not disclosed. More details.... Share this with colleagues: